[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Oculus Technologies of Mexico, S.A. de C.V.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":116},{"warningLetters":4,"total":115},[5,31,51,73,94],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},3456,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2021-03-16T13:20:00Z\">03\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-11T05:00:00Z\">03\u002F11\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Falbek-de-mexico-sa-de-cv-609202-03112021\">Albek de Mexico S.A. de C.V.\u003C\u002Fa>","Center for Drug Evaluation and Research","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. José Manuel Beltrán Mendoza\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u002FPresident\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Albek de Mexico S.A. de C.V.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Oriente 4 No. 11\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nuevo Parque Industrial\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>76809\u003C\u002Fspan> \u003Cspan>San Juan del Río\u003C\u002Fspan>, \u003Cspan>Qro.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-21-35\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nMarch 11, 2021\u003Cbr>\n\u003Cbr>\nDear Mr. Beltrán Mendoza:\u003C\u002Fp>\n\n\u003Cp>Your firm is registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic rub drug product (also referred to as a consumer hand sanitizer), labeled as NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER. This drug product was declared to be manufactured at your facility, Albek de Mexico S.A. de C.V., FEI 3009115034, at Oriente 4 No. 11, Nuevo Parque Industrial, San Juan del Río, Queretaro, Mexico. Following an attempt to import NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER into the United States, it was detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of the FDA laboratory testing of batches of this product detained at the border demonstrate that this drug product declared to be manufactured at your facility is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>In addition, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(j), (a), (e), and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), (e), and (ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER, declared to be manufactured at your facility, is labeled to contain 70% volume\u002Fvolume (v\u002Fv) of the active ingredient alcohol (ethanol). However, FDA laboratory testing of batches of this product detained at the border found that one batch contained an average of 39% ethanol and an average of 27% methanol v\u002Fv. A second batch contained an average of 38% ethanol and an average of 27% methanol v\u002Fv. A third batch contained an average of 55% ethanol and an average of 10% methanol v\u002Fv. A fourth batch contained on average of 37% ethanol and an average of 29% methanol v\u002Fv. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&amp;C Act in that the active ingredient, ethanol, was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\u003C\u002Fp>\n\n\u003Cp>Methanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products, and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning.\u003C\u002Fp>\n\n\u003Cp>On July 27, 2020, FDA held a teleconference with you and Registrar Corporation, your registered U.S. Agent. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market. On July 28, 2020, FDA notified the public of the methanol contamination of your hand sanitizer drug products at the following website: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>On July 31, 2020, you issued a voluntary nationwide recall of NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER due to potential presence of undeclared methanol (wood alcohol), as noted on the following FDA website: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Falbek-de-mexico-sa-de-cv-issues-voluntary-nationwide-recall-all-hand-sanitizers-due-potential#:~:text=SAN%20JUAN%20del%20RIO%20QUERETARO,2019%20and%20June%2028%2C%202020\">https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Falbek-de-mexico-sa-de-cv-issues-voluntary-nationwide-recall-all-hand-sanitizers-due-potential#:~:text=SAN%20JUAN%20del%20RIO%20QUERETARO,2019%20and%20June%2028%2C%202020\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed investigation into how the drug product described above, which was declared to be manufactured at your facility and which was labeled as containing ethanol, was substituted in part or in whole with methanol.\u003C\u002Fli>\n\t\u003Cli>A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\u003C\u002Fli>\n\t\u003Cli>A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\u003C\u002Fli>\n\t\u003Cli>Copies of the complete batch records for all batches distributed to the U.S.\u003C\u002Fli>\n\t\u003Cli>Provide your test methods for testing raw materials and your hand sanitizer drug products. If you intend to accept any results from your supplier’s Certificate of Analysis instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. We note that identity testing is required for every lot of components regardless of supplier test result validation. Your policy should include a requirement that you test every lot of ethanol you receive for methanol content using the United States Pharmacopeia (USP) method in a CGMP compliant laboratory.\u003C\u002Fli>\n\t\u003Cli>Discuss the corrective action to test all of your drug products prior to release for strength and identity of the active ingredient.\u003C\u002Fli>\n\t\u003Cli>In correspondence received from your customer’s outside counsel it was stated your firm conducted raw material and finished product testing and confirmed the purity of the ethanol used in hand sanitizer lots. FDA test results demonstrate substitution of methanol for ethanol in your hand sanitizer drug products and call into question the purity of the ethanol used to manufacture them. FDA questions the validity of test results generated by your facility or by others on your behalf. Provide a complete, comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The substitution and contamination with methanol in a drug product declared to be manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic hand rub.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER product label and labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>Drug Facts . . . Uses ·\u003C\u002Fstrong> To decrease bacteria on the skin when water, soap &amp; towel are not available.”\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>Directions\u003C\u002Fstrong> . . . Apply enough product to wet hands. Rub hands together until dry. Supervise children in use of this product.”\u003C\u002Fp>\n\n\u003Cp>This topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to the product label, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER purportedly contains the active ingredient ethyl alcohol 70% v\u002Fv. However, as previously discussed, FDA laboratory analyses of batches of this product detained at the border demonstrated that NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER contain ethyl alcohol in a concentration that is less than the 70% v\u002Fv stated on its product label and less than the amount of ethyl alcohol described in the 1994 TFM.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Such a product does not conform with the TFM or the applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>FDA laboratory analyses also demonstrated that batches of NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER contain significant concentrations of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the 1994 TFM, nor is methanol included in the formulations described in FDA’s \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> Guidance for Industry. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Additionally, this methanol-containing drug product, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER, is misbranded under sections 502(j), (a), (e), and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), (e), and (ee). It is misbranded under section 502(j) of the FD&amp;C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death.\u003C\u002Fp>\n\n\u003Cp>This hand sanitizer is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because its labeling is false or misleading. As noted above, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is labeled to contain ethyl alcohol 70% v\u002Fv. However, FDA laboratory analysis of batches of this product demonstrates that the product contains a concentration of ethyl alcohol (ethanol) that is less than what is stated on the product label and contains a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product label. Section 201(n) of the FD&amp;C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result . . .” Thus, the misleading representation of the concentration of the active ingredient ethyl alcohol (ethanol), and the failure of the product label to disclose the presence of the methyl alcohol (methanol) in the product, causes this product to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\n\n\u003Cp>The failure of this drug product to list methyl alcohol (methanol) as an ingredient on its label causes it to be misbranded under section 502(e)(1)(A) of the FD&amp;C Act, 21 U.S.C. 352(e)(1)(A).\u003C\u002Fp>\n\n\u003Cp>Lastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on August 4, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&amp;C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Please identify your response with FEI 3009115034 and ATTN: Tamara Rosbury.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\nRegistered U.S. Agent\u003Cbr>\nDavid Lennarz\u003Cbr>\nRegistrar Corporation\u003Cbr>\n144 Research Drive\u003Cbr>\nHampton, VA, 23666\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>\u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong>\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative testing results detailed above that demonstrate the substitution of hand sanitizer products declared as manufactured at your facility, a review of the purported formulations on the drug products’ labeling further indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., \u003Cem>\u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong>\u003C\u002Fem>. Because NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is not consistent with the formulations in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> An inactive ingredient used in over-the-counter (OTC) monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. José Manuel Beltrán Mendoza\n\nRecipient Title\n\nCEO\u002FPresident\n\nAlbek de Mexico S.A. de C.V.\n\nOriente 4 No. 11\n\nNuevo Parque Industrial\n\n76809 San Juan del Río, Qro.\n\nMexico\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research\n\nUnited States\n\nWarning Letter 320-21-35\n\nMarch 11, 2021\n\nDear Mr. Beltrán Mendoza:\n\nYour firm is registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic rub drug product (also referred to as a consumer hand sanitizer), labeled as NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER. This drug product was declared to be manufactured at your facility, Albek de Mexico S.A. de C.V., FEI 3009115034, at Oriente 4 No. 11, Nuevo Parque Industrial, San Juan del Río, Queretaro, Mexico. Following an attempt to import NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER into the United States, it was detained and refused admission at the border.\n\nThe results of the FDA laboratory testing of batches of this product detained at the border demonstrate that this drug product declared to be manufactured at your facility is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nIn addition, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), (e), and (ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nAdulteration Violations\n\nNEXT ADVANCED ANTIBACTERIAL HAND SANITIZER, declared to be manufactured at your facility, is labeled to contain 70% volume\u002Fvolume (v\u002Fv) of the active ingredient alcohol (ethanol). However, FDA laboratory testing of batches of this product detained at the border found that one batch contained an average of 39% ethanol and an average of 27% methanol v\u002Fv. A second batch contained an average of 38% ethanol and an average of 27% methanol v\u002Fv. A third batch contained an average of 55% ethanol and an average of 10% methanol v\u002Fv. A fourth batch contained on average of 37% ethanol and an average of 29% methanol v\u002Fv. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&C Act in that the active ingredient, ethanol, was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\n\nMethanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products, and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning.\n\nOn July 27, 2020, FDA held a teleconference with you and Registrar Corporation, your registered U.S. Agent. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market. On July 28, 2020, FDA notified the public of the methanol contamination of your hand sanitizer drug products at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\n\nOn July 31, 2020, you issued a voluntary nationwide recall of NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER due to potential presence of undeclared methanol (wood alcohol), as noted on the following FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Falbek-de-mexico-sa-de-cv-issues-voluntary-nationwide-recall-all-hand-sanitizers-due-potential#:~:text=SAN%20JUAN%20del%20RIO%20QUERETARO,2019%20and%20June%2028%2C%202020.\n\nIn response to this letter provide the following:\n\nA detailed investigation into how the drug product described above, which was declared to be manufactured at your facility and which was labeled as containing ethanol, was substituted in part or in whole with methanol.\n\nA list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\n\nA list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\n\nCopies of the complete batch records for all batches distributed to the U.S.\n\nProvide your test methods for testing raw materials and your hand sanitizer drug products. If you intend to accept any results from your supplier’s Certificate of Analysis instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. We note that identity testing is required for every lot of components regardless of supplier test result validation. Your policy should include a requirement that you test every lot of ethanol you receive for methanol content using the United States Pharmacopeia (USP) method in a CGMP compliant laboratory.\n\nDiscuss the corrective action to test all of your drug products prior to release for strength and identity of the active ingredient.\n\nIn correspondence received from your customer’s outside counsel it was stated your firm conducted raw material and finished product testing and confirmed the purity of the ethanol used in hand sanitizer lots. FDA test results demonstrate substitution of methanol for ethanol in your hand sanitizer drug products and call into question the purity of the ethanol used to manufacture them. FDA questions the validity of test results generated by your facility or by others on your behalf. Provide a complete, comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nThe substitution and contamination with methanol in a drug product declared to be manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act.1\n\nUnapproved New Drug and Misbranding Violations\n\nNEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic hand rub.\n\nExamples of claims observed on the NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER product label and labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“Drug Facts . . . Uses · To decrease bacteria on the skin when water, soap & towel are not available.”\n\n“Directions . . . Apply enough product to wet hands. Rub hands together until dry. Supervise children in use of this product.”\n\nThis topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAccording to the product label, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER purportedly contains the active ingredient ethyl alcohol 70% v\u002Fv. However, as previously discussed, FDA laboratory analyses of batches of this product detained at the border demonstrated that NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER contain ethyl alcohol in a concentration that is less than the 70% v\u002Fv stated on its product label and less than the amount of ethyl alcohol described in the 1994 TFM.2 Such a product does not conform with the TFM or the applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.3\n\nFDA laboratory analyses also demonstrated that batches of NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER contain significant concentrations of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the 1994 TFM, nor is methanol included in the formulations described in FDA’s Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Guidance for Industry. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.4\n\nAdditionally, this methanol-containing drug product, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER, is misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), (e), and (ee). It is misbranded under section 502(j) of the FD&C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death.\n\nThis hand sanitizer is misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because its labeling is false or misleading. As noted above, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is labeled to contain ethyl alcohol 70% v\u002Fv. However, FDA laboratory analysis of batches of this product demonstrates that the product contains a concentration of ethyl alcohol (ethanol) that is less than what is stated on the product label and contains a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product label. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result . . .” Thus, the misleading representation of the concentration of the active ingredient ethyl alcohol (ethanol), and the failure of the product label to disclose the presence of the methyl alcohol (methanol) in the product, causes this product to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\n\nThe failure of this drug product to list methyl alcohol (methanol) as an ingredient on its label causes it to be misbranded under section 502(e)(1)(A) of the FD&C Act, 21 U.S.C. 352(e)(1)(A).\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on August 4, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\n\nPlease identify your response with FEI 3009115034 and ATTN: Tamara Rosbury.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\ncc:\n\nRegistered U.S. Agent\n\nDavid Lennarz\n\nRegistrar Corporation\n\n144 Research Drive\n\nHampton, VA, 23666\n\n_________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative testing results detailed above that demonstrate the substitution of hand sanitizer products declared as manufactured at your facility, a review of the purported formulations on the drug products’ labeling further indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n2 The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\n\n3 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is not consistent with the formulations in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.\n\n4 An inactive ingredient used in over-the-counter (OTC) monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.","Albek de Mexico S.A. de C.V.","albek-de-mexico-sa-de-cv-609202-03112021","2026-08-18T06:42:29.386127+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Falbek-de-mexico-sa-de-cv-609202-03112021","2026-10-26T08:07:52.082237+00:00","Warning Letter","Issued","2021-03-16","609202","Drugs","Mr. José Manuel Beltrán Mendoza","2026-08-20T03:16:15.6+00:00","VIA UPS","2021-03-11",{"id":32,"raw":33,"subject":12,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":48,"body_fetched_at":49,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},3562,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2021-02-02T14:20:00Z\">02\u002F02\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-01-26T05:00:00Z\">01\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgrupo-yacana-mexico-sas-de-cv-609824-01262021\">Grupo Yacana Mexico, S.A.S. de C.V.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Sofia Corona Gonzalez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Laboratory and Production Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Grupo Yacana Mexico, S.A.S. de C.V.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Av. Alfonso Reyes No. 714\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Country la Silla Sector 4\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>67173\u003C\u002Fspan> \u003Cspan>Guadalupe\u003C\u002Fspan>, \u003Cspan>N.L.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-21-20\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 26, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Sofia Corona Gonzalez:\u003C\u002Fp>\n\n\u003Cp>Your firm recently registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of consumer antiseptic hand rub drug products (also referred to as consumer hand sanitizers) labeled as YACANA Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub. These drug products were labeled as manufactured at your facility, Grupo Yacana Mexico, S.A.S. de C.V., FEI 3015123543, at Av. Alfonso Reyes No. 714, Guadalupe (Country la Silla Sector 4), Nuevo Leon, Mexico. Following an attempt to import YACANA Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub into the United States, they were detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of FDA laboratory testing of batches of these products detained at the border demonstrate that the YACANA Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub drug products, labeled as manufactured at your facility, are adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor.\u003C\u002Fp>\n\n\u003Cp>The results of FDA laboratory testing of a batch of YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub drug product, labeled as manufactured at your facility, is adulterated within the meaning of section 501(c) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or Act), 21 U.S.C. 351(c), in that its strength, purity, or quality falls below that which it purports or represents to possess.\u003C\u002Fp>\n\n\u003Cp>These products are also adulterated within the meaning of section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)), in that the substitution and subpotency demonstrate that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003Cbr>\n\u003Cbr>\nIn addition, your YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and are misbranded under sections (a) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(a) and (ee). YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub is further misbranded under sections 502(j) and (e) of the FD&amp;C Act, 21 U.S.C. 352(j), and (e). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations: Substitution\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>YACANA Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub, labeled as manufactured at your facility, is labeled to contain 70% volume\u002Fvolume (v\u002Fv) of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of one batch of this product detained at the border found that the drug product contained on average 0.04% ethanol v\u002Fv and an average of 63% methanol v\u002Fv. FDA laboratory testing of another batch of this product detained at the border found on average 3.6% ethanol v\u002Fv and an average of 59% methanol v\u002Fv. FDA laboratory testing of a third batch of this product detained at the border found on average 0.6% ethanol v\u002Fv and an average of 49% methanol v\u002Fv.\u003C\u002Fp>\n\n\u003Cp>Methanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidently ingest these products, and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning.\u003C\u002Fp>\n\n\u003Cp>Additionally, YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub, labeled as manufactured at your facility, is labeled to contain 70% (v\u002Fv) of the active ingredient Isopropyl Alcohol (IPA). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained on average of 53% ethanol v\u002Fv and 0% (v\u002Fv) IPA.\u003C\u002Fp>\n\n\u003Cp>Therefore, these hand sanitizer drug products are adulterated under section 501(d)(2) of the FD&amp;C Act in that the active ingredient of ethanol was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations: Subpotency\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub, labeled as manufactured at your facility, is labeled to contain 70% (v\u002Fv) of the active ingredient isopropyl alcohol (IPA). However, FDA laboratory testing of a batch of this product detained at the border found that it contained 61% IPA (v\u002Fv) and 0.7% ethanol (v\u002Fv). This hand sanitizer drug product is adulterated under section 501(c) of the FD&amp;C Act in that the active ingredient of IPA is present at levels in the product lower than that which is declared on its labeling. CDC recommends\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 70% IPA. This is the minimum active ingredient concentration of IPA specified in the 1994 Tentative Final Monograph for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by the “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\u003C\u002Fp>\n\n\u003Cp>On August 12, 2020, FDA held a teleconference with you and Pragmatic Compliance LLC, your registered U.S. Agent. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market. FDA notified the public of the subpotency and methanol contamination of your hand sanitizer drug products at the following webpage: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>On August 18, 2020, you issued a voluntary nationwide recall of all your hand sanitizer drug products due to the presence of undeclared methanol (Wood Alcohol) and subpotent ethanol, as noted on the following webpage:\u003Cbr>\n\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fgrupo-yacana-mexico-sas-de-cv-issues-voluntary-nationwide-recall-all-lots-yacana-hand-sanitizer-due\">https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fgrupo-yacana-mexico-sas-de-cv-issues-voluntary-nationwide-recall-all-lots-yacana-hand-sanitizer-due\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>In response to this letter provide the following:\u003Cbr>\n• A detailed investigation into how the drug products described above, which were labeled as manufactured at your facility and which were labeled as containing ethanol or IPA, were substituted in part or in whole with methanol or ethanol, respectively.\u003Cbr>\n• A detailed investigation into how the hand sanitizer drug products described above, which were labeled as containing 70% IPA, in fact contained an average of 61% IPA (v\u002Fv).\u003Cbr>\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the supplier’s names, addresses, and contact information.\u003Cbr>\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\u003Cbr>\n• Copies of the complete batch records for all batches distributed to the U.S.\u003C\u002Fp>\n\n\u003Cp>The substitution and contamination with methanol in hand sanitizer drug products labeled as manufactured in your facility, as well as the subpotency of hand sanitizer products labeled as manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as consumer antiseptic rubs.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub product labels that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; “Drug Facts…Uses…Hand Sanitizer to help reduce bacteria that potentially can cause disease…”\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; “Directions…Place enough product to cover all surfaces, rub hand together until dry…”\u003C\u002Fp>\n\n\u003Cp>These topical antiseptic products are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for these products, as further described below). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for either of these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub drug products are GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the FDA’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\u003C\u002Fp>\n\n\u003Cp>Over the course of these rulemakings, benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol were classified as Category III for use as active ingredients in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub. Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 -- and that were not classified as Category II for safety or effectiveness -- are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rub proposed, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to the product label, YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub purportedly contains the active ingredient ethyl alcohol (ethanol) 70% v\u002Fv. However, as previously discussed, FDA laboratory analyses of batches of these products detained at the border demonstrated that YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub contains ethanol in a concentration that is less than the 70% stated on its product label and far less than the amount of ethanol described in the 1994 TFM.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Such a product does not conform to the TFM or applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>FDA laboratory analyses of batches of this product detained at the border revealed that batches of YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub contain significant concentrations of the undeclared ingredient, methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the TFM, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>According to its label, YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub purportedly contains the active ingredient isopropyl alcohol 70% v\u002Fv. However, as previously discussed, FDA laboratory analyses revealed that batches of these products detained at the border contain isopropyl alcohol, which is less than the 70% stated on its product label and less than the amount of isopropyl alcohol described in the 1994 TFM. Furthermore, the analyses revealed that the product contained concentrations of an undeclared ingredient, ethanol. Ethanol as a sole active ingredient is permitted for use as a consumer or health care personnel antiseptic hand rub. However, even if ethanol was intended to be the only active ingredient for the product, the concentrations of the undeclared ingredient is below the concentration allowed under the TFM. Such a product does not conform to the TFM or applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003C\u002Fp>\n\n\u003Cp>Additionally, YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub is misbranded under sections 502(j), (a), (e), and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), and (e). YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub is misbranded under sections 502(a) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(a) and (ee).\u003C\u002Fp>\n\n\u003Cp>YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub is misbranded under section 502(j) of the FD&amp;C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death. The failure of this product to list methanol as an ingredient on its label also causes YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub to be misbranded under section 502(e)(1)(A) of the FD&amp;C Act, 21 U.S.C. 352(e)(1)(A).\u003C\u002Fp>\n\n\u003Cp>YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because their labeling is false or misleading. Section 201(n) of the FD&amp;C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result. . ..” As noted above, of YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub is labeled to contain ethanol 70% v\u002Fv. However, FDA laboratory analyses of batches of this product demonstrate that the product contains a concentration of ethanol that is far less than the 70% stated on the product label and instead contains significant concentrations of methanol, an ingredient that is not declared on the product labels. Similarly, as noted above, Yacana Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub is labeled to contain isopropyl alcohol 70% v\u002Fv. However, FDA laboratory analyses of batches of this product demonstrate that the product contains isopropyl alcohol, which is less than the 70% stated on its product label and contains ethanol even though the product label does not include ethanol as an ingredient. Thus, the misleading representation of the concentration of active ingredient ethanol and the failure of the product label to disclose the presence of the methanol in the product, causes YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\n\n\u003Cp>Lastly, YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because they are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and they are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified, as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements, if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on August 20, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Identify your response with FEI 3015123543 and ATTN: Philip Kreiter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRegistered U.S. Agent\u003Cbr>\nMr. Jerry Doane\u003Cbr>\nPragmatic Compliance LLC\u003Cbr>\n15815 SW 11th Court Rd.\u003Cbr>\nOcala, FL 34473\u003Cbr>\nUSA\u003C\u002Fp>\n\n\u003Cp>_______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> \u003Ca href=\"https:\u002F\u002Fwww.cdc.gov\u002Fcoronavirus\u002F2019-ncov\u002Fhcp\u002Fhand-hygiene.html\">https:\u002F\u002Fwww.cdc.gov\u002Fcoronavirus\u002F2019-ncov\u002Fhcp\u002Fhand-hygiene.html\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on August 7, 2020. This guidance communicates the Agency’s temporary policy that we&nbsp;do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rubs) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the substitution and contamination of methanol in hand sanitizer products labeled as manufactured at your facility, as well as the subpotency of hand sanitizer products labeled as manufactured at your facility, a review of the drug products’ labeling further indicate that these products are not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, these products do not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are not consistent with the formulations described in these guidances, they do not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> An inactive ingredient used in over-the-counter (OTC) monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Sofia Corona Gonzalez\n\nRecipient Title\n\nLaboratory and Production Manager\n\nGrupo Yacana Mexico, S.A.S. de C.V.\n\nAv. Alfonso Reyes No. 714\n\nCountry la Silla Sector 4\n\n67173 Guadalupe, N.L.\n\nMexico\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-21-20\n\nJanuary 26, 2021\n\nDear Ms. Sofia Corona Gonzalez:\n\nYour firm recently registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of consumer antiseptic hand rub drug products (also referred to as consumer hand sanitizers) labeled as YACANA Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub. These drug products were labeled as manufactured at your facility, Grupo Yacana Mexico, S.A.S. de C.V., FEI 3015123543, at Av. Alfonso Reyes No. 714, Guadalupe (Country la Silla Sector 4), Nuevo Leon, Mexico. Following an attempt to import YACANA Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub into the United States, they were detained and refused admission at the border.\n\nThe results of FDA laboratory testing of batches of these products detained at the border demonstrate that the YACANA Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub drug products, labeled as manufactured at your facility, are adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor.\n\nThe results of FDA laboratory testing of a batch of YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub drug product, labeled as manufactured at your facility, is adulterated within the meaning of section 501(c) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or Act), 21 U.S.C. 351(c), in that its strength, purity, or quality falls below that which it purports or represents to possess.\n\nThese products are also adulterated within the meaning of section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)), in that the substitution and subpotency demonstrate that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nIn addition, your YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and are misbranded under sections (a) and (ee) of the FD&C Act, 21 U.S.C. 352(a) and (ee). YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub is further misbranded under sections 502(j) and (e) of the FD&C Act, 21 U.S.C. 352(j), and (e). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a).\n\nAdulteration Violations: Substitution\n\nYACANA Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub, labeled as manufactured at your facility, is labeled to contain 70% volume\u002Fvolume (v\u002Fv) of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of one batch of this product detained at the border found that the drug product contained on average 0.04% ethanol v\u002Fv and an average of 63% methanol v\u002Fv. FDA laboratory testing of another batch of this product detained at the border found on average 3.6% ethanol v\u002Fv and an average of 59% methanol v\u002Fv. FDA laboratory testing of a third batch of this product detained at the border found on average 0.6% ethanol v\u002Fv and an average of 49% methanol v\u002Fv.\n\nMethanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidently ingest these products, and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning.\n\nAdditionally, YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub, labeled as manufactured at your facility, is labeled to contain 70% (v\u002Fv) of the active ingredient Isopropyl Alcohol (IPA). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained on average of 53% ethanol v\u002Fv and 0% (v\u002Fv) IPA.\n\nTherefore, these hand sanitizer drug products are adulterated under section 501(d)(2) of the FD&C Act in that the active ingredient of ethanol was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\n\nAdulteration Violations: Subpotency\n\nYACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub, labeled as manufactured at your facility, is labeled to contain 70% (v\u002Fv) of the active ingredient isopropyl alcohol (IPA). However, FDA laboratory testing of a batch of this product detained at the border found that it contained 61% IPA (v\u002Fv) and 0.7% ethanol (v\u002Fv). This hand sanitizer drug product is adulterated under section 501(c) of the FD&C Act in that the active ingredient of IPA is present at levels in the product lower than that which is declared on its labeling. CDC recommends1 that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 70% IPA. This is the minimum active ingredient concentration of IPA specified in the 1994 Tentative Final Monograph for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by the “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\n\nOn August 12, 2020, FDA held a teleconference with you and Pragmatic Compliance LLC, your registered U.S. Agent. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market. FDA notified the public of the subpotency and methanol contamination of your hand sanitizer drug products at the following webpage: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\n\nOn August 18, 2020, you issued a voluntary nationwide recall of all your hand sanitizer drug products due to the presence of undeclared methanol (Wood Alcohol) and subpotent ethanol, as noted on the following webpage:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fgrupo-yacana-mexico-sas-de-cv-issues-voluntary-nationwide-recall-all-lots-yacana-hand-sanitizer-due\n\nIn response to this letter provide the following:\n\n• A detailed investigation into how the drug products described above, which were labeled as manufactured at your facility and which were labeled as containing ethanol or IPA, were substituted in part or in whole with methanol or ethanol, respectively.\n\n• A detailed investigation into how the hand sanitizer drug products described above, which were labeled as containing 70% IPA, in fact contained an average of 61% IPA (v\u002Fv).\n\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the supplier’s names, addresses, and contact information.\n\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\n\n• Copies of the complete batch records for all batches distributed to the U.S.\n\nThe substitution and contamination with methanol in hand sanitizer drug products labeled as manufactured in your facility, as well as the subpotency of hand sanitizer products labeled as manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act.2\n\nUnapproved New Drug and Misbranding Violations\n\nYACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as consumer antiseptic rubs.\n\nExamples of claims observed on the YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub product labels that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n\n“Drug Facts…Uses…Hand Sanitizer to help reduce bacteria that potentially can cause disease…”\n\n“Directions…Place enough product to cover all surfaces, rub hand together until dry…”\n\nThese topical antiseptic products are “new drugs” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for these products, as further described below). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for either of these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub drug products are GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the FDA’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\n\nOver the course of these rulemakings, benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol were classified as Category III for use as active ingredients in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub. Section 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 -- and that were not classified as Category II for safety or effectiveness -- are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rub proposed, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAccording to the product label, YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub purportedly contains the active ingredient ethyl alcohol (ethanol) 70% v\u002Fv. However, as previously discussed, FDA laboratory analyses of batches of these products detained at the border demonstrated that YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub contains ethanol in a concentration that is less than the 70% stated on its product label and far less than the amount of ethanol described in the 1994 TFM.3 Such a product does not conform to the TFM or applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.4\n\nFDA laboratory analyses of batches of this product detained at the border revealed that batches of YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub contain significant concentrations of the undeclared ingredient, methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the TFM, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.5\n\nAccording to its label, YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub purportedly contains the active ingredient isopropyl alcohol 70% v\u002Fv. However, as previously discussed, FDA laboratory analyses revealed that batches of these products detained at the border contain isopropyl alcohol, which is less than the 70% stated on its product label and less than the amount of isopropyl alcohol described in the 1994 TFM. Furthermore, the analyses revealed that the product contained concentrations of an undeclared ingredient, ethanol. Ethanol as a sole active ingredient is permitted for use as a consumer or health care personnel antiseptic hand rub. However, even if ethanol was intended to be the only active ingredient for the product, the concentrations of the undeclared ingredient is below the concentration allowed under the TFM. Such a product does not conform to the TFM or applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\n\nAdditionally, YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub is misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), and (e). YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub is misbranded under sections 502(a) and (ee) of the FD&C Act, 21 U.S.C. 352(a) and (ee).\n\nYACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub is misbranded under section 502(j) of the FD&C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death. The failure of this product to list methanol as an ingredient on its label also causes YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub to be misbranded under section 502(e)(1)(A) of the FD&C Act, 21 U.S.C. 352(e)(1)(A).\n\nYACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because their labeling is false or misleading. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result. . ..” As noted above, of YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub is labeled to contain ethanol 70% v\u002Fv. However, FDA laboratory analyses of batches of this product demonstrate that the product contains a concentration of ethanol that is far less than the 70% stated on the product label and instead contains significant concentrations of methanol, an ingredient that is not declared on the product labels. Similarly, as noted above, Yacana Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub is labeled to contain isopropyl alcohol 70% v\u002Fv. However, FDA laboratory analyses of batches of this product demonstrate that the product contains isopropyl alcohol, which is less than the 70% stated on its product label and contains ethanol even though the product label does not include ethanol as an ingredient. Thus, the misleading representation of the concentration of active ingredient ethanol and the failure of the product label to disclose the presence of the methanol in the product, causes YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\n\nLastly, YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because they are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and they are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified, as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements, if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on August 20, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov\n\nIdentify your response with FEI 3015123543 and ATTN: Philip Kreiter.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nRegistered U.S. Agent\n\nMr. Jerry Doane\n\nPragmatic Compliance LLC\n\n15815 SW 11th Court Rd.\n\nOcala, FL 34473\n\nUSA\n\n_______________________________\n\n1 https:\u002F\u002Fwww.cdc.gov\u002Fcoronavirus\u002F2019-ncov\u002Fhcp\u002Fhand-hygiene.html\n\n2 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on August 7, 2020. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rubs) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the substitution and contamination of methanol in hand sanitizer products labeled as manufactured at your facility, as well as the subpotency of hand sanitizer products labeled as manufactured at your facility, a review of the drug products’ labeling further indicate that these products are not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, these products do not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n3 The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\n\n4 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are not consistent with the formulations described in these guidances, they do not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.\n\n5 An inactive ingredient used in over-the-counter (OTC) monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.","Grupo Yacana Mexico, S.A.S. de C.V.","grupo-yacana-mexico-sas-de-cv-609824-01262021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgrupo-yacana-mexico-sas-de-cv-609824-01262021","2026-10-26T08:08:50.901888+00:00","2021-02-02","609824","Ms. Sofia Corona Gonzalez","2026-08-20T03:25:10.775+00:00","2021-01-26",{"id":52,"raw":53,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":63,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":68,"closeout_date":19,"issuing_office":57,"recipient_name":69,"body_fetched_at":70,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},2979,[54,55,56,57,58,13,13,13],"\u003Ctime datetime=\"2021-12-14T14:20:00Z\">12\u002F14\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-30T05:00:00Z\">11\u002F30\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdental-technologies-inc-612599-11302021\">Dental Technologies Inc.\u003C\u002Fa>","Division of Pharmaceutical Quality Operations III","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Stephen A. Erickson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Co-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Dental Technologies Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6901 N. Hamlin Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lincolnwood\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60712\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nWL # 612599\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 30, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Erickson:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug and medical device manufacturing facility, Dental Technologies Inc., FEI 1413475, at 6901 N. Hamlin Avenue, Lincolnwood, Illinois from December 7, 2020, to January 20, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals and Quality System (QS) regulations for medical devices. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211) and Title 21 CFR, part 820, respectively.\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>Additionally, your drug product, Paroex 0.12% chlorhexidine oral rinse, is adulterated under section 501(a)(2)(A) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(A), in that a substance was prepared, packed, or held under insanitary conditions, whereby it may have become contaminated with filth and rendered injurious to health.\u003C\u002Fp>\n\n\u003Cp>Under section 201(h) of the FD&amp;C Act, 21 U.S.C. § 321(h), G•U•M® HYDRAL™ OTC products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. The HYDRAL™ OTC products are intended for treatment of Xerostomia\u002Fdry mouth.\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that your devices are adulterated within the meaning of section 501(h) of the FD&amp;C Act, 21 U.S.C. § 351(h) because the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We reviewed your February 10, 2021, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You lack adequate investigations into failing microbiological results for both finished drug products and components.\u003C\u002Fp>\n\n\u003Cp>A. In October 2020, your third-party laboratory identified \u003Cem>Burkholderia cepacia\u003C\u002Fem> complex (BCC), specifically \u003Cem>Burkholderia lata\u003C\u002Fem> in Paroex 0.12% chlorhexidine oral rinse. Until prompted by FDA, your investigation failed to adequately evaluate excessive aerobic plate counts (including too numerous to count (TNTC)) and past BCC contamination events at your facility. Your investigation did not adequately address multiple potential root causes of the contamination. For example, we noted that your cleaning program was deficient. Notably, a lack of cleaning competency extended to multiple products made at your facility, and in one instance cleaning procedures had to be repeated two or more times to assure their efficacy.\u003C\u002Fp>\n\n\u003Cp>You failed to implement systemic corrective actions and preventive actions (CAPA) and investigate additional lots that may have been affected.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response, which includes your firm’s updated investigation, was inadequate.\u003C\u002Fp>\n\n\u003Cp>• Your investigation did not sufficiently address the TNTC levels of microorganisms in numerous Paroex batch retain samples, including the inability of the formulation to exert any meaningful inhibitory effect on microbial growth in your product.\u003C\u002Fp>\n\n\u003Cp>• Your investigation did not adequately explain the extreme variability of results within batches, including TNTC and passing results obtained from testing of multiple retain samples from the same batch. Also, you did not adequately describe how your future sampling strategy will be improved to provide better understanding of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>• You identified the chlorhexidine gluconate active pharmaceutical ingredient (API) as the most likely root cause of the Paroex contamination, but your investigation lacked justification for this assertion. For example:\u003Cbr>\n&nbsp; &nbsp; o The investigation indicated the API supplier found \u003Cem>Serratia marcescens\u003C\u002Fem> in certain lots of their chlorhexidine gluconate API, and this caused it to be the likely source of the BCC contamination. However, you noted the API supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, recalled affected lots contaminated with \u003Cem>Serratia marcescens\u003C\u002Fem> and your API lots met microbiological specifications. Further, your investigation lacks any indication that BCC had been isolated during chlorhexidine gluconate testing by either your supplier or your laboratory.\u003Cbr>\n&nbsp; &nbsp; o The investigation failed to address that, in addition to the lack of data indicating the presence of BCC in your API, BCC is very different from \u003Cem>Serratia marcescens\u003C\u002Fem> as they are in different taxonomic classes and have significantly different phenotypic and genotypic characteristics.\u003C\u002Fp>\n\n\u003Cp>• Your response states your Paroex 0.12% chlorhexidine gluconate oral rinse release testing did not detect \u003Cem>Burkholderia lata\u003C\u002Fem> because of a low level of contamination. This conclusion is flawed since you were not testing your product for BCC at the time, and your test method was inadequate to reliably detect these microorganisms.\u003C\u002Fp>\n\n\u003Cp>• Your response states shared equipment was cleaned and sanitized before use, per your procedures. However, your response lacks evidence of traceability confirming that the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, identified as a potential cause of contamination, was adequately cleaned, and sanitized before use during manufacturing.\u003C\u002Fp>\n\n\u003Cp>• Your response acknowledges that the use of ancillary equipment is not documented in your batch records. However, you failed to include systemic corrections to your batch records and documentation systems to ensure traceability of each piece of equipment used during manufacturing, including but not limited to, their use, cleaning, sanitization, calibration, and maintenance.\u003C\u002Fp>\n\n\u003Cp>• You failed to adequately explain how you will systemically remediate your investigations program to ensure investigations are thorough, root causes are appropriately identified, scope of impacted products is appropriately evaluated, and CAPAs are prompt and effective.\u003C\u002Fp>\n\n\u003Cp>The Paroex product owner released a public announcement on December 28, 2020, detailing the receipt of a significant number of adverse events (29) associated with the product. Affected patients who received Paroex 0.12% chlorhexidine oral rinse tested positive for \u003Cem>Burkholderia lata\u003C\u002Fem>. Use of the contaminated product in patients who are immunocompromised or have pre-existing respiratory conditions, including critically ill patients and patients infected with COVID-19, is especially concerning as these patients are at increased risk for serious and life-threatening infections.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that batches of Paroex 0.12% chlorhexidine gluconate oral rinse bearing an expiration date from June 30 to September 30, 2022, were recalled on October 27, 2020. It was not until further discussions with FDA that the recall was extended to other potentially impacted batches of Paroex 0.12% chlorhexidine gluconate oral rinse products, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products.\u003C\u002Fp>\n\n\u003Cp>In addition, FDA collected a sample of Paroex 0.12% chlorhexidine oral rinse lot C219DQ. Our testing revealed BCC contamination and failing total counts, which further demonstrated insanitary conditions (501(a)(2)(A)) at your facility.\u003C\u002Fp>\n\n\u003Cp>B. Your firm invalidated failing microbiological results obtained by your third-party laboratory during stability testing of a batch of AlphaCaine topical anesthetic gel in March 2019, without scientific justification.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Pseudomonas aeruginosa\u003C\u002Fem> was isolated from the product sample and your laboratory retested the product. Your investigation determined your test method to be unsuitable because “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” After retesting with a method your laboratory determined suitable, you obtained passing results.\u003C\u002Fp>\n\n\u003Cp>Your investigation concluded, without adequate supporting evidence, that your third-party laboratory “may have contaminated the sample,” though they indicated no laboratory error had occurred and results were reproducible. Further, although you acknowledge your original test method for AlphaCaine topical anesthetic gel was inappropriate, your investigation determined “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\n\n\u003Cp>Your firm’s response is inadequate. You failed to perform a thorough evaluation of test methods used to ensure their adequacy.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• Your procedures describing in-process and finished product sampling and testing. Address how you will ensure samples are representative and can detect variation within a batch. Include how testing of individual samples (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) will be better leveraged to evaluate uniformity throughout the process.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive and independent assessment of your manufacturing processes to determine the current state of control as well as to determine if any process remediation and new validation studies are necessary. This assessment should include, but not be limited to, a study to extensively assess intra\u002Finter-batch uniformity for all appropriate attributes of your drug products.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your water system design, control, and maintenance. Include a description of all areas in your water system that can be stagnant.\u003C\u002Fp>\n\n\u003Cp>• A retrospective, independent review of all batch failures, rejected batches, returned drug products, complaints, and deviations that may have been related to microbiological contamination for the last three years.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fp>\n\n\u003Cp>• A retrospective, independent review of all invalidated OOS results (including in-process, release, and stability testing) for products currently in the U.S. market and within expiry as of the date of this letter. Include a report summarizing the findings of the analysis, detailing the following for each OOS:\u003Cbr>\n&nbsp; &nbsp; o Determine whether the scientific justification and evidence relating to the invalidated OOS results conclusively or inconclusively demonstrate causative laboratory error.\u003Cbr>\n&nbsp; &nbsp; o For investigations that conclusively establish laboratory root cause, provide rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>\n&nbsp; &nbsp; o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, addressing the following:\u003Cbr>\n&nbsp; &nbsp; o Quality unit oversight of laboratory investigations\u003Cbr>\n&nbsp; &nbsp; o Identification of adverse laboratory control trends\u003Cbr>\n&nbsp; &nbsp; o Resolution of causes of laboratory variation\u003Cbr>\n&nbsp; &nbsp; o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>\n&nbsp; &nbsp; o Adequately scoping of each investigation and its CAPA\u003Cbr>\n&nbsp; &nbsp; o Revised OOS investigation procedures with these and other remediations.\u003C\u002Fp>\n\n\u003Cp>• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, and contemporaneous records throughout your operation.\u003Cbr>\n\u003Cbr>\n• Documentation to confirm the identity, cleaning, and sanitization of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of Paroex 0.12% chlorhexidine oral rinse, starting with lot C170FY. Specify the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in lot C170FY and each following lot.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your non-sterile aqueous-based drug product specifications did not include \u003Cem>Burkholderia cepacia\u003C\u002Fem> until October 2020. In 2012, you had identified \u003Cem>Burkholderia cepacia\u003C\u002Fem> testing as a requirement for chlorhexidine in your OOS investigation #268. However, you did not update your finished product specifications to include this testing until after Paroex 0.12% chlorhexidine oral rinse manufactured at your facility was found contaminated with \u003Cem>Burkholderia cepacia\u003C\u002Fem> complex in 2020.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You stated that the testing protocol submitted in the Paroex 0.12% chlorhexidine oral rinse drug application did not include \u003Cem>Burkholderia cepacia\u003C\u002Fem>, and that the United States Pharmacopeia (USP) General Chapter &lt;1111&gt; lacks explicit reference to \u003Cem>Burkholderia cepacia\u003C\u002Fem> complex.\u003C\u002Fp>\n\n\u003Cp>Your response states that you “followed the guidance outlined in” USP General Chapter &lt;1111&gt;. You add that “USP &lt;1111&gt; does not require testing these products for the absence of \u003Cem>B. cepacia\u003C\u002Fem>.”\u003C\u002Fp>\n\n\u003Cp>It should be noted that USP &lt;1111&gt; states that the list of specified microbes “is not necessarily exhaustive, and for a given preparation it may be necessary to test for other microorganisms.” Per USP, “the significance of other organisms recovered should be evaluated” considering multiple factors. Finally, USP &lt;1111&gt; is an informational chapter, and does not establish “requirements” or CGMP expectations.\u003C\u002Fp>\n\n\u003Cp>It is critical that firms establish scientifically sound and appropriate specifications for total count limits and freedom from objectionable microorganisms. Release testing under CGMP may include, but not be limited to, methods found in a drug application, those found in USP test chapters, and any additional tests as per 21 CFR 211.160. While USP methods are often incorporated into the release regimen, the methods are not necessarily batch release standards and may be insufficient to fully characterize the microbiological quality of a drug. USP chapters do not focus on identification of microbes, although this is essential to detect significant opportunistic pathogens in certain products. It is also important to note that USP acknowledges non-monograph tests and acceptance criteria may be necessary in addition to tests in the individual monograph. This is because it is manifestly impossible for each USP monograph to include all potential impurities and contaminants, including microbial contamination.\u003C\u002Fp>\n\n\u003Cp>While it may be impractical for each potentially objectionable microbe to be exhaustively listed in a specification, it is important that microbial flora found in your drug products be appropriately evaluated. This evaluation should include consideration of the full spectrum of patients who could receive your products based on their intended use. Such assessments should include input from qualified staff, such as individuals with strong microbiology and clinical expertise.\u003C\u002Fp>\n\n\u003Cp>Your firm continued to release drug products without BCC testing and did not update specifications until October 2020.\u003C\u002Fp>\n\n\u003Cp>Your drugs are often used in hospital or clinical settings in which patients may have a higher vulnerability to infection with \u003Cem>Burkholderia cepacia\u003C\u002Fem> and other objectionable organisms. Detecting numbers and types of objectionable microorganisms in your drug products is critical to making appropriate batch disposition decisions.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system (including ensuring adequacy of testing functions performed by a third-party laboratory on your behalf).\u003C\u002Fp>\n\n\u003Cp>• A list of microbial specifications, including test methods, used to analyze each lot of your drug products before release to ensure they are appropriate for their intended use. Also include the formulas (ingredients; percent composition) for each drug product, and state whether you will be testing batches for BCC as part of release testing. Release testing specifications should be developed based, in part, on your formulation and validated manufacturing steps to ensure your aqueous drug products are free from BCC.\u003C\u002Fp>\n\n\u003Cp>• An action plan and timelines for conducting full microbiological testing of retain samples to determine the quality of all batches of drug product with aqueous formulations distributed to the United States that are within expiry as of the date of this letter (if not already retrospectively tested). Include a summary of all results obtained from testing retain samples from each batch within expiry. You should test microbiological quality (total counts; identification of bioburden to detect objectionable microbes) of each batch. If such testing reveals an OOS result or otherwise indicates substandard quality, take rapid corrective actions, such as notifying customers and assessment for product recalls.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards and a CAPA plan that describes improvements to design and control.\u003C\u002Fp>\n\n\u003Cp>• Complete retrospective investigations into all batches with potential objectionable microbial contamination or an OOS microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity,&nbsp;strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not adequately validate the processes used to clean your non-dedicated, product-contact equipment.\u003C\u002Fp>\n\n\u003Cp>A. You observed residue on \u003Cstrong>(b)(4)\u003C\u002Fstrong> during the 0.12% chlorhexidine gluconate oral rinse cleaning validation. Although you documented the deviation, you did not identify the residue. You determined that no corrective action was necessary, and your cleaning procedures remained unchanged. You selected 0.12% chlorhexidine gluconate oral rinse for your cleaning validation study because you manufacture the drug product \u003Cstrong>(b)(4)\u003C\u002Fstrong> and claim that it represents other water-based rinses manufactured in the shared equipment.\u003C\u002Fp>\n\n\u003Cp>B. Adequate validation or verification studies are not always performed when introducing \u003Cstrong>(b)(4)\u003C\u002Fstrong> risk products (e.g., difficult to clean, low solubility) into the non-dedicated equipment. For example, you neither incorporated Oral Cleansing Gel, 1.7% hydrogen peroxide into your \u003Cstrong>(b)(4)\u003C\u002Fstrong>-based cleaning validation matrix nor performed cleaning verification to evaluate the cleanability of this new, more viscous product.\u003C\u002Fp>\n\n\u003Cp>C. A \u003Cstrong>(b)(4)\u003C\u002Fstrong> was \u003Cstrong>(b)(4)\u003C\u002Fstrong> when failing microbiological results were obtained during the 0.12% chlorhexidine gluconate oral rinse cleaning validation. Your cleaning procedures were not updated to reflect the need for this additional \u003Cstrong>(b)(4)\u003C\u002Fstrong> performed during the validation.\u003C\u002Fp>\n\n\u003Cp>D. Your cleaning validation studies do not include all product-contact manufacturing equipment, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>E. Your procedures are \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lack specificity to ensure repeatability, and do not require equipment to be \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure hard to reach areas are cleaned properly.\u003C\u002Fp>\n\n\u003Cp>Cleaning programs should be designed to ensure equipment is consistently and properly cleaned to prevent contamination. Inadequate removal of residues from product contact surfaces of non-dedicated manufacturing equipment during cleaning can lead to cross-contamination of drug products subsequently manufactured on that equipment.\u003C\u002Fp>\n\n\u003Cp>We acknowledge you updated cleaning procedures and commit to perform additional validations as needed. However, your response did not adequately assess the risk of potential cross-contamination and its effect on product quality for batches of drug product manufactured on this shared equipment.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated drug products may have been released for distribution. The\u003Cbr>\nassessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fp>\n\n\u003Cp>• A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all drug products and equipment; and all other needed remediations.\u003C\u002Fp>\n\n\u003Cp>• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst-case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Recovery studies to ensure swab sample results are reliable and meaningful\u003Cbr>\n&nbsp; &nbsp; o Maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or new product.\u003C\u002Fp>\n\n\u003Cp>• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for drug products, processes, and equipment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your manufacturing equipment is not designed and maintained appropriately.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Upon our request, you \u003Cstrong>(b)(4)\u003C\u002Fstrong> installed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Our investigators observed residue inside the \u003Cstrong>(b)(4)\u003C\u002Fstrong> after the equipment had been cleaned and sanitized. Also during our inspection, \u003Cem>Pseudomonas aeruginosa\u003C\u002Fem> was isolated from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located on another manufacturing \u003Cstrong>(b)(4)\u003C\u002Fstrong>. \u003Cstrong>(b)(4)\u003C\u002Fstrong> are not easily cleanable (including sanitizable) and can contribute to contamination.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate.\u003C\u002Fp>\n\n\u003Cp>• You stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> would have been \u003Cstrong>(b)(4)\u003C\u002Fstrong> because it was outside the \u003Cstrong>(b)(4)\u003C\u002Fstrong> clean hold time. However, you failed to explain why these residues were present after the equipment had already been cleaned and sanitized per your validated procedure.\u003C\u002Fp>\n\n\u003Cp>• You stated that the white residue was “most likely residual \u003Cstrong>(b)(4)\u003C\u002Fstrong> from the hand sanitizer product.” However, after manufacturing the hand sanitizer, \u003Cstrong>(b)(4)\u003C\u002Fstrong> had been cleaned, sanitized, and used to make another product, hydrogen peroxide rinse, 1.5% w\u002Fw. Your response lacks evidence to support your hypothesis regarding the identity of the residues.\u003C\u002Fp>\n\n\u003Cp>• You indicated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> will solve this insanitary design problem and commit to implement procedures to \u003Cstrong>(b)(4)\u003C\u002Fstrong> as part of routine cleaning. You did not provide any mitigating action until this CAPA intended to remediate the cleaning issue is implemented. You continue to manufacture and release drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Backflow Prevention Systems\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> connected to \u003Cstrong>(b)(4)\u003C\u002Fstrong> lacked an effective backflow prevention system to prevent contamination of drug product from downstream equipment. Upon request by our investigators, your firm swabbed the visibly contaminated and thoroughly \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Numerous microorganisms, including \u003Cem>Pseudomonas aeruginosa, Enterobacter cloacae\u003C\u002Fem>, and \u003Cem>Klebsiella oxytoca\u003C\u002Fem>, were recovered. You were unable to provide any evidence the insanitary \u003Cstrong>(b)(4)\u003C\u002Fstrong> had been changed since it was installed. Equipment used in pharmaceutical manufacturing operations should be maintained in sanitary condition, and it is critical for certain equipment to be designed with a backflow prevention system to protect drug products from contamination.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. The process flow diagram included in your response shows \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> also use the same \u003Cstrong>(b)(4)\u003C\u002Fstrong> as \u003Cstrong>(b)(4)\u003C\u002Fstrong> without any mechanism to prevent backflow. The process flow diagram does not provide sufficient assurance of effective backflow prevention mechanisms to protect each of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> associated with the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response does not evaluate drug products manufactured in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Production Oversight and Equipment Maintenance\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>In addition, your production management does not ensure the equipment used in the manufacture of drug products is suitable for its intended use and is properly maintained.\u003C\u002Fp>\n\n\u003Cp>Although the aforementioned \u003Cstrong>(b)(4)\u003C\u002Fstrong> was manifestly contaminated for an extended period, your production management failed to identify and remove the insanitary filter from use.\u003C\u002Fp>\n\n\u003Cp>Our investigators also observed packaging tape being used to seal the outside of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your employees explained that the packaging tape was being used so that the equipment would be able to hold a \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You stated that you repaired the kettle and commit to prevent unapproved maintenance activity in the future. However, there is no evidence that you performed a thorough evaluation of the current state of your manufacturing equipment. Also, you did not state how you were going to improve \u003Cstrong>(b)(4)\u003C\u002Fstrong> oversight of your facility and equipment.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• Your CAPA plan to implement \u003Cstrong>(b)(4)\u003C\u002Fstrong> operations management oversight of facilities and equipment. This plan should ensure, among other things, evaluating suitability of equipment for its intended use, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fp>\n\n\u003Cp>• An independent, third-party review to evaluate objectively the sanitary design of your facilities and equipment, and to assess the adequacy of maintenance and control practices. Provide a detailed summary of their assessment and associated CAPA activities you will be undertaking.\u003C\u002Fp>\n\n\u003Cp>• Updated diagrams clearly identifying the \u003Cstrong>(b)(4)\u003C\u002Fstrong> located between the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the associated \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Medical Device Quality System Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). Specifically, a nonconformance was not generated after the filling line mechanic found the \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;used on filling line \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Hydral Dry Mouth Spray, Lot C164FT). The master filling\u002Fpackaging batch record for Hydral Dry Mouth Spray, Lot C164FT section 2.2.5 requires the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>The filter event was discussed in your out-of-specification investigation OOS-907 in response to the test results indicating \u003Cem>Burkholderia\u003C\u002Fem>, sp. contamination of the Hydral Dry Mouth Spray, Lot C164FT. The OOS-907 report confirmed that upon deconstruction of the filter housing that the filter was not connected to the cap and that product could have bypassed the filter. The OOS-907 states that the filter was not likely effective throughout the entire fill of the lot. Although the cause for the \u003Cem>Burkholderia\u003C\u002Fem> in the lot was attributed to contaminated product provided by the primary manufacturer and formula owner, you failed to adequately investigate the filter nonconformance.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response does not adequately address the observation. For example, your firm’s response indicates that your Out of Specification (OOS) procedure QSP 14.03 does not require \u003Cstrong>(b)(4)\u003C\u002Fstrong>. There was no evaluation into the cause of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used on filling line \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Hydral Dry Mouth Spray, Lot C164FT). Your firm’s response further states that you do not use \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the filling of any other products and that the Hydral Dry Mouth Spray will no longer be filled by DTI. The evaluation of nonconformances and the need for a timely investigation is essential to protecting against recurrence. Your firm has not established adequate OOS procedures to ensure the identification, documentation, evaluation, segregation and disposition of nonconforming product by DTI personnel.\u003C\u002Fp>\n\n\u003Cp>2. Failure to conduct, control and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70. Specifically, the Master Filling\u002FPackaging batch record for Hydral Dry Mouth Spray, Lot C164FT section 2.2.5 requires the use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> by the line mechanic \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the Hydral Dry Mouth Spray, Lot C164FT. Your firm’s OOS-907 states that the filter was likely not effective throughout the entire fill of the lot.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response is inadequate in that the corrective actions taken by your firm are not complete and appropriate to remedy the deficiencies identified on Observation 5 of the form FDA 483, Inspectional Observations. Your firm failed to adequately address the lack of process controls in the manufacture of Hydral Dry Mouth Spray. Your response states that the Hydral Dry Mouth Spray is the only product that uses the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and that your firm has discontinued manufacturing the product. The response is inadequate in that it does not address the underlying issue regarding the monitoring of controlled processes to ensure they remain in control. This affects all processes that can have an impact on product specifications for all products manufactured at your firm and is not limited to the Hydral Dry Mouth Spray filling operations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: Q8(R2) Pharmaceutical Development at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq8r2-pharmaceutical-development\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq8r2-pharmaceutical-development\u003C\u002Fa>, Q9 Quality Risk Management at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq9-quality-risk-management\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq9-quality-risk-management\u003C\u002Fa>, and Q10 Pharmaceutical Quality System at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq10-pharmaceutical-quality-system\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq10-pharmaceutical-quality-system\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Objectionable Organisms\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>For further information regarding the significance of \u003Cem>B. cepacia\u003C\u002Fem> complex and other objectionable contamination of non-sterile, water-based drug products, see FDA’s advisory notice posted on July 7, 2021, at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDrugSafety\u002Fucm559508.htm\">https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDrugSafety\u002Fucm559508.htm\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to cease production of 0.12% chlorhexidine oral rinse.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, clarify whether you intend to resume manufacturing this drug for the U.S. market at this facility in the future. If you plan to resume manufacturing 0.12% chlorhexidine oral rinse for the U.S. market, notify this office before resuming your operations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with application sponsors and product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility\u002Fin connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (612599). Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Russell K. Riley, Compliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Russell K. Riley at (630) 277-1908.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Nicholas F. Lyons\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Blake Bevill, M.S.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Devices and Radiological Health\u003Cbr>\nOperations Div. 2 Central\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Stephen A. Erickson\n\nRecipient Title\n\nPresident and Co-Owner\n\nDental Technologies Inc.\n\n6901 N. Hamlin Avenue\n\nLincolnwood, IL 60712\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nWARNING LETTER\n\nWL # 612599\n\nNovember 30, 2021\n\nDear Mr. Erickson:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug and medical device manufacturing facility, Dental Technologies Inc., FEI 1413475, at 6901 N. Hamlin Avenue, Lincolnwood, Illinois from December 7, 2020, to January 20, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals and Quality System (QS) regulations for medical devices. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211) and Title 21 CFR, part 820, respectively.\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nAdditionally, your drug product, Paroex 0.12% chlorhexidine oral rinse, is adulterated under section 501(a)(2)(A) of the FD&C Act, 21 U.S.C. 351(a)(2)(A), in that a substance was prepared, packed, or held under insanitary conditions, whereby it may have become contaminated with filth and rendered injurious to health.\n\nUnder section 201(h) of the FD&C Act, 21 U.S.C. § 321(h), G•U•M® HYDRAL™ OTC products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. The HYDRAL™ OTC products are intended for treatment of Xerostomia\u002Fdry mouth.\n\nThis inspection also revealed that your devices are adulterated within the meaning of section 501(h) of the FD&C Act, 21 U.S.C. § 351(h) because the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation.\n\nDrug CGMP Violations\n\nWe reviewed your February 10, 2021, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYou lack adequate investigations into failing microbiological results for both finished drug products and components.\n\nA. In October 2020, your third-party laboratory identified Burkholderia cepacia complex (BCC), specifically Burkholderia lata in Paroex 0.12% chlorhexidine oral rinse. Until prompted by FDA, your investigation failed to adequately evaluate excessive aerobic plate counts (including too numerous to count (TNTC)) and past BCC contamination events at your facility. Your investigation did not adequately address multiple potential root causes of the contamination. For example, we noted that your cleaning program was deficient. Notably, a lack of cleaning competency extended to multiple products made at your facility, and in one instance cleaning procedures had to be repeated two or more times to assure their efficacy.\n\nYou failed to implement systemic corrective actions and preventive actions (CAPA) and investigate additional lots that may have been affected.\n\nYour firm’s response, which includes your firm’s updated investigation, was inadequate.\n\n• Your investigation did not sufficiently address the TNTC levels of microorganisms in numerous Paroex batch retain samples, including the inability of the formulation to exert any meaningful inhibitory effect on microbial growth in your product.\n\n• Your investigation did not adequately explain the extreme variability of results within batches, including TNTC and passing results obtained from testing of multiple retain samples from the same batch. Also, you did not adequately describe how your future sampling strategy will be improved to provide better understanding of (b)(4).\n\n• You identified the chlorhexidine gluconate active pharmaceutical ingredient (API) as the most likely root cause of the Paroex contamination, but your investigation lacked justification for this assertion. For example:\n\no The investigation indicated the API supplier found Serratia marcescens in certain lots of their chlorhexidine gluconate API, and this caused it to be the likely source of the BCC contamination. However, you noted the API supplier, (b)(4), recalled affected lots contaminated with Serratia marcescens and your API lots met microbiological specifications. Further, your investigation lacks any indication that BCC had been isolated during chlorhexidine gluconate testing by either your supplier or your laboratory.\n\no The investigation failed to address that, in addition to the lack of data indicating the presence of BCC in your API, BCC is very different from Serratia marcescens as they are in different taxonomic classes and have significantly different phenotypic and genotypic characteristics.\n\n• Your response states your Paroex 0.12% chlorhexidine gluconate oral rinse release testing did not detect Burkholderia lata because of a low level of contamination. This conclusion is flawed since you were not testing your product for BCC at the time, and your test method was inadequate to reliably detect these microorganisms.\n\n• Your response states shared equipment was cleaned and sanitized before use, per your procedures. However, your response lacks evidence of traceability confirming that the (b)(4), identified as a potential cause of contamination, was adequately cleaned, and sanitized before use during manufacturing.\n\n• Your response acknowledges that the use of ancillary equipment is not documented in your batch records. However, you failed to include systemic corrections to your batch records and documentation systems to ensure traceability of each piece of equipment used during manufacturing, including but not limited to, their use, cleaning, sanitization, calibration, and maintenance.\n\n• You failed to adequately explain how you will systemically remediate your investigations program to ensure investigations are thorough, root causes are appropriately identified, scope of impacted products is appropriately evaluated, and CAPAs are prompt and effective.\n\nThe Paroex product owner released a public announcement on December 28, 2020, detailing the receipt of a significant number of adverse events (29) associated with the product. Affected patients who received Paroex 0.12% chlorhexidine oral rinse tested positive for Burkholderia lata. Use of the contaminated product in patients who are immunocompromised or have pre-existing respiratory conditions, including critically ill patients and patients infected with COVID-19, is especially concerning as these patients are at increased risk for serious and life-threatening infections.\n\nWe acknowledge that batches of Paroex 0.12% chlorhexidine gluconate oral rinse bearing an expiration date from June 30 to September 30, 2022, were recalled on October 27, 2020. It was not until further discussions with FDA that the recall was extended to other potentially impacted batches of Paroex 0.12% chlorhexidine gluconate oral rinse products, (b)(4), and (b)(4) drug products.\n\nIn addition, FDA collected a sample of Paroex 0.12% chlorhexidine oral rinse lot C219DQ. Our testing revealed BCC contamination and failing total counts, which further demonstrated insanitary conditions (501(a)(2)(A)) at your facility.\n\nB. Your firm invalidated failing microbiological results obtained by your third-party laboratory during stability testing of a batch of AlphaCaine topical anesthetic gel in March 2019, without scientific justification.\n\nPseudomonas aeruginosa was isolated from the product sample and your laboratory retested the product. Your investigation determined your test method to be unsuitable because “(b)(4).” After retesting with a method your laboratory determined suitable, you obtained passing results.\n\nYour investigation concluded, without adequate supporting evidence, that your third-party laboratory “may have contaminated the sample,” though they indicated no laboratory error had occurred and results were reproducible. Further, although you acknowledge your original test method for AlphaCaine topical anesthetic gel was inappropriate, your investigation determined “(b)(4).”\n\nYour firm’s response is inadequate. You failed to perform a thorough evaluation of test methods used to ensure their adequacy.\n\nIn response to this letter, provide:\n\n• Your procedures describing in-process and finished product sampling and testing. Address how you will ensure samples are representative and can detect variation within a batch. Include how testing of individual samples ((b)(4)) will be better leveraged to evaluate uniformity throughout the process.\n\n• A comprehensive and independent assessment of your manufacturing processes to determine the current state of control as well as to determine if any process remediation and new validation studies are necessary. This assessment should include, but not be limited to, a study to extensively assess intra\u002Finter-batch uniformity for all appropriate attributes of your drug products.\n\n• A comprehensive, independent assessment of your water system design, control, and maintenance. Include a description of all areas in your water system that can be stagnant.\n\n• A retrospective, independent review of all batch failures, rejected batches, returned drug products, complaints, and deviations that may have been related to microbiological contamination for the last three years.\n\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\n• A retrospective, independent review of all invalidated OOS results (including in-process, release, and stability testing) for products currently in the U.S. market and within expiry as of the date of this letter. Include a report summarizing the findings of the analysis, detailing the following for each OOS:\n\no Determine whether the scientific justification and evidence relating to the invalidated OOS results conclusively or inconclusively demonstrate causative laboratory error.\n\no For investigations that conclusively establish laboratory root cause, provide rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\n\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\n\n• A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, addressing the following:\n\no Quality unit oversight of laboratory investigations\n\no Identification of adverse laboratory control trends\n\no Resolution of causes of laboratory variation\n\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\n\no Adequately scoping of each investigation and its CAPA\n\no Revised OOS investigation procedures with these and other remediations.\n\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, and contemporaneous records throughout your operation.\n\n• Documentation to confirm the identity, cleaning, and sanitization of the (b)(4) used in the manufacture of Paroex 0.12% chlorhexidine oral rinse, starting with lot C170FY. Specify the (b)(4) used in lot C170FY and each following lot.\n\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nYour non-sterile aqueous-based drug product specifications did not include Burkholderia cepacia until October 2020. In 2012, you had identified Burkholderia cepacia testing as a requirement for chlorhexidine in your OOS investigation #268. However, you did not update your finished product specifications to include this testing until after Paroex 0.12% chlorhexidine oral rinse manufactured at your facility was found contaminated with Burkholderia cepacia complex in 2020.\n\nYour response is inadequate. You stated that the testing protocol submitted in the Paroex 0.12% chlorhexidine oral rinse drug application did not include Burkholderia cepacia, and that the United States Pharmacopeia (USP) General Chapter \u003C1111> lacks explicit reference to Burkholderia cepacia complex.\n\nYour response states that you “followed the guidance outlined in” USP General Chapter \u003C1111>. You add that “USP \u003C1111> does not require testing these products for the absence of B. cepacia.”\n\nIt should be noted that USP \u003C1111> states that the list of specified microbes “is not necessarily exhaustive, and for a given preparation it may be necessary to test for other microorganisms.” Per USP, “the significance of other organisms recovered should be evaluated” considering multiple factors. Finally, USP \u003C1111> is an informational chapter, and does not establish “requirements” or CGMP expectations.\n\nIt is critical that firms establish scientifically sound and appropriate specifications for total count limits and freedom from objectionable microorganisms. Release testing under CGMP may include, but not be limited to, methods found in a drug application, those found in USP test chapters, and any additional tests as per 21 CFR 211.160. While USP methods are often incorporated into the release regimen, the methods are not necessarily batch release standards and may be insufficient to fully characterize the microbiological quality of a drug. USP chapters do not focus on identification of microbes, although this is essential to detect significant opportunistic pathogens in certain products. It is also important to note that USP acknowledges non-monograph tests and acceptance criteria may be necessary in addition to tests in the individual monograph. This is because it is manifestly impossible for each USP monograph to include all potential impurities and contaminants, including microbial contamination.\n\nWhile it may be impractical for each potentially objectionable microbe to be exhaustively listed in a specification, it is important that microbial flora found in your drug products be appropriately evaluated. This evaluation should include consideration of the full spectrum of patients who could receive your products based on their intended use. Such assessments should include input from qualified staff, such as individuals with strong microbiology and clinical expertise.\n\nYour firm continued to release drug products without BCC testing and did not update specifications until October 2020.\n\nYour drugs are often used in hospital or clinical settings in which patients may have a higher vulnerability to infection with Burkholderia cepacia and other objectionable organisms. Detecting numbers and types of objectionable microorganisms in your drug products is critical to making appropriate batch disposition decisions.\n\nIn response to this letter, provide:\n\n• A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system (including ensuring adequacy of testing functions performed by a third-party laboratory on your behalf).\n\n• A list of microbial specifications, including test methods, used to analyze each lot of your drug products before release to ensure they are appropriate for their intended use. Also include the formulas (ingredients; percent composition) for each drug product, and state whether you will be testing batches for BCC as part of release testing. Release testing specifications should be developed based, in part, on your formulation and validated manufacturing steps to ensure your aqueous drug products are free from BCC.\n\n• An action plan and timelines for conducting full microbiological testing of retain samples to determine the quality of all batches of drug product with aqueous formulations distributed to the United States that are within expiry as of the date of this letter (if not already retrospectively tested). Include a summary of all results obtained from testing retain samples from each batch within expiry. You should test microbiological quality (total counts; identification of bioburden to detect objectionable microbes) of each batch. If such testing reveals an OOS result or otherwise indicates substandard quality, take rapid corrective actions, such as notifying customers and assessment for product recalls.\n\n• A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards and a CAPA plan that describes improvements to design and control.\n\n• Complete retrospective investigations into all batches with potential objectionable microbial contamination or an OOS microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\n\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYou did not adequately validate the processes used to clean your non-dedicated, product-contact equipment.\n\nA. You observed residue on (b)(4) during the 0.12% chlorhexidine gluconate oral rinse cleaning validation. Although you documented the deviation, you did not identify the residue. You determined that no corrective action was necessary, and your cleaning procedures remained unchanged. You selected 0.12% chlorhexidine gluconate oral rinse for your cleaning validation study because you manufacture the drug product (b)(4) and claim that it represents other water-based rinses manufactured in the shared equipment.\n\nB. Adequate validation or verification studies are not always performed when introducing (b)(4) risk products (e.g., difficult to clean, low solubility) into the non-dedicated equipment. For example, you neither incorporated Oral Cleansing Gel, 1.7% hydrogen peroxide into your (b)(4)-based cleaning validation matrix nor performed cleaning verification to evaluate the cleanability of this new, more viscous product.\n\nC. A (b)(4) was (b)(4) when failing microbiological results were obtained during the 0.12% chlorhexidine gluconate oral rinse cleaning validation. Your cleaning procedures were not updated to reflect the need for this additional (b)(4) performed during the validation.\n\nD. Your cleaning validation studies do not include all product-contact manufacturing equipment, such as (b)(4).\n\nE. Your procedures are (b)(4), lack specificity to ensure repeatability, and do not require equipment to be (b)(4) to ensure hard to reach areas are cleaned properly.\n\nCleaning programs should be designed to ensure equipment is consistently and properly cleaned to prevent contamination. Inadequate removal of residues from product contact surfaces of non-dedicated manufacturing equipment during cleaning can lead to cross-contamination of drug products subsequently manufactured on that equipment.\n\nWe acknowledge you updated cleaning procedures and commit to perform additional validations as needed. However, your response did not adequately assess the risk of potential cross-contamination and its effect on product quality for batches of drug product manufactured on this shared equipment.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated drug products may have been released for distribution. The\n\nassessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\n• A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all drug products and equipment; and all other needed remediations.\n\n• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst-case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Recovery studies to ensure swab sample results are reliable and meaningful\n\no Maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or new product.\n\n• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for drug products, processes, and equipment.\n\n4. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63)\n\nYour manufacturing equipment is not designed and maintained appropriately.\n\n(b)(4)\n\nUpon our request, you (b)(4) installed on (b)(4). Our investigators observed residue inside the (b)(4) after the equipment had been cleaned and sanitized. Also during our inspection, Pseudomonas aeruginosa was isolated from (b)(4) located on another manufacturing (b)(4). (b)(4) are not easily cleanable (including sanitizable) and can contribute to contamination.\n\nYour response is inadequate.\n\n• You stated that (b)(4) would have been (b)(4) because it was outside the (b)(4) clean hold time. However, you failed to explain why these residues were present after the equipment had already been cleaned and sanitized per your validated procedure.\n\n• You stated that the white residue was “most likely residual (b)(4) from the hand sanitizer product.” However, after manufacturing the hand sanitizer, (b)(4) had been cleaned, sanitized, and used to make another product, hydrogen peroxide rinse, 1.5% w\u002Fw. Your response lacks evidence to support your hypothesis regarding the identity of the residues.\n\n• You indicated that (b)(4) will solve this insanitary design problem and commit to implement procedures to (b)(4) as part of routine cleaning. You did not provide any mitigating action until this CAPA intended to remediate the cleaning issue is implemented. You continue to manufacture and release drug products.\n\nBackflow Prevention Systems\n\nYour (b)(4) connected to (b)(4) lacked an effective backflow prevention system to prevent contamination of drug product from downstream equipment. Upon request by our investigators, your firm swabbed the visibly contaminated and thoroughly (b)(4) and (b)(4). Numerous microorganisms, including Pseudomonas aeruginosa, Enterobacter cloacae, and Klebsiella oxytoca, were recovered. You were unable to provide any evidence the insanitary (b)(4) had been changed since it was installed. Equipment used in pharmaceutical manufacturing operations should be maintained in sanitary condition, and it is critical for certain equipment to be designed with a backflow prevention system to protect drug products from contamination.\n\nYour response is inadequate. The process flow diagram included in your response shows (b)(4) and (b)(4) also use the same (b)(4) as (b)(4) without any mechanism to prevent backflow. The process flow diagram does not provide sufficient assurance of effective backflow prevention mechanisms to protect each of the (b)(4) associated with the (b)(4). Your response does not evaluate drug products manufactured in (b)(4) and (b)(4).\n\nProduction Oversight and Equipment Maintenance\n\nIn addition, your production management does not ensure the equipment used in the manufacture of drug products is suitable for its intended use and is properly maintained.\n\nAlthough the aforementioned (b)(4) was manifestly contaminated for an extended period, your production management failed to identify and remove the insanitary filter from use.\n\nOur investigators also observed packaging tape being used to seal the outside of a (b)(4) on (b)(4). Your employees explained that the packaging tape was being used so that the equipment would be able to hold a (b)(4).\n\nYour response is inadequate. You stated that you repaired the kettle and commit to prevent unapproved maintenance activity in the future. However, there is no evidence that you performed a thorough evaluation of the current state of your manufacturing equipment. Also, you did not state how you were going to improve (b)(4) oversight of your facility and equipment.\n\nIn response to this letter, provide:\n\n• Your CAPA plan to implement (b)(4) operations management oversight of facilities and equipment. This plan should ensure, among other things, evaluating suitability of equipment for its intended use, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\n• An independent, third-party review to evaluate objectively the sanitary design of your facilities and equipment, and to assess the adequacy of maintenance and control practices. Provide a detailed summary of their assessment and associated CAPA activities you will be undertaking.\n\n• Updated diagrams clearly identifying the (b)(4) located between the (b)(4) and the associated (b)(4).\n\nMedical Device Quality System Violations\n\n1. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). Specifically, a nonconformance was not generated after the filling line mechanic found the (b)(4) used on filling line (b)(4) (Hydral Dry Mouth Spray, Lot C164FT). The master filling\u002Fpackaging batch record for Hydral Dry Mouth Spray, Lot C164FT section 2.2.5 requires the (b)(4).\n\nThe filter event was discussed in your out-of-specification investigation OOS-907 in response to the test results indicating Burkholderia, sp. contamination of the Hydral Dry Mouth Spray, Lot C164FT. The OOS-907 report confirmed that upon deconstruction of the filter housing that the filter was not connected to the cap and that product could have bypassed the filter. The OOS-907 states that the filter was not likely effective throughout the entire fill of the lot. Although the cause for the Burkholderia in the lot was attributed to contaminated product provided by the primary manufacturer and formula owner, you failed to adequately investigate the filter nonconformance.\n\nYour firm’s response does not adequately address the observation. For example, your firm’s response indicates that your Out of Specification (OOS) procedure QSP 14.03 does not require (b)(4). There was no evaluation into the cause of the (b)(4) used on filling line (b)(4) (Hydral Dry Mouth Spray, Lot C164FT). Your firm’s response further states that you do not use (b)(4) for the filling of any other products and that the Hydral Dry Mouth Spray will no longer be filled by DTI. The evaluation of nonconformances and the need for a timely investigation is essential to protecting against recurrence. Your firm has not established adequate OOS procedures to ensure the identification, documentation, evaluation, segregation and disposition of nonconforming product by DTI personnel.\n\n2. Failure to conduct, control and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70. Specifically, the Master Filling\u002FPackaging batch record for Hydral Dry Mouth Spray, Lot C164FT section 2.2.5 requires the use of the (b)(4). The (b)(4) by the line mechanic (b)(4) for the Hydral Dry Mouth Spray, Lot C164FT. Your firm’s OOS-907 states that the filter was likely not effective throughout the entire fill of the lot.\n\nYour firm’s response is inadequate in that the corrective actions taken by your firm are not complete and appropriate to remedy the deficiencies identified on Observation 5 of the form FDA 483, Inspectional Observations. Your firm failed to adequately address the lack of process controls in the manufacture of Hydral Dry Mouth Spray. Your response states that the Hydral Dry Mouth Spray is the only product that uses the (b)(4) and that your firm has discontinued manufacturing the product. The response is inadequate in that it does not address the underlying issue regarding the monitoring of controlled processes to ensure they remain in control. This affects all processes that can have an impact on product specifications for all products manufactured at your firm and is not limited to the Hydral Dry Mouth Spray filling operations.\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: Q8(R2) Pharmaceutical Development at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq8r2-pharmaceutical-development, Q9 Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq9-quality-risk-management, and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq10-pharmaceutical-quality-system.\n\nObjectionable Organisms\n\nFor further information regarding the significance of B. cepacia complex and other objectionable contamination of non-sterile, water-based drug products, see FDA’s advisory notice posted on July 7, 2021, at https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDrugSafety\u002Fucm559508.htm.\n\nDrug Production Ceased\n\nWe acknowledge your commitment to cease production of 0.12% chlorhexidine oral rinse.\n\nIn response to this letter, clarify whether you intend to resume manufacturing this drug for the U.S. market at this facility in the future. If you plan to resume manufacturing 0.12% chlorhexidine oral rinse for the U.S. market, notify this office before resuming your operations.\n\nResponsibilities as a Contractor\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with application sponsors and product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility\u002Fin connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to the Warning Letter Number above (612599). Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Russell K. Riley, Compliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations Division III\n\nIf you have questions regarding the contents of this letter, please contact Russell K. Riley at (630) 277-1908.\n\nSincerely,\n\n\u002FS\u002F\n\nNicholas F. Lyons\n\nActing Program Division Director\n\nDivision of Pharmaceutical Quality Operations Division III\n\nSincerely,\n\n\u002FS\u002F\n\nBlake Bevill, M.S.\n\nProgram Division Director\n\nOffice of Medical Devices and Radiological Health\n\nOperations Div. 2 Central","Dental Technologies Inc.","dental-technologies-inc-612599-11302021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdental-technologies-inc-612599-11302021","2026-10-26T08:08:22.930897+00:00","2021-12-14","612599","Medical Devices","Mr. Stephen A. Erickson","2026-08-20T02:20:38.474+00:00","UPS","2021-11-30",{"id":74,"raw":75,"subject":80,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":63,"fei_number":19,"letter_url":85,"updated_at":86,"action_type":22,"case_status":23,"posted_date":87,"marcs_cms_no":88,"product_type":89,"closeout_date":19,"issuing_office":79,"recipient_name":90,"body_fetched_at":91,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":93,"medical_device_id":19,"response_letter_date":19},2904,[76,77,78,79,80,13,13,13],"\u003Ctime datetime=\"2022-01-25T14:20:00Z\">01\u002F25\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-01-21T05:00:00Z\">01\u002F21\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsas-technologies-inc-dba-save-smoker-625483-01212022\">SAS Technologies, Inc d\u002Fb\u002Fa Save A Smoker\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Erick Slaick\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>SAS Technologies, Inc d\u002Fb\u002Fa Save A Smoker\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4074 S US Hwy 231F Suite B\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ozark\u003C\u002Fspan>, \u003Cspan>AL\u003C\u002Fspan> \u003Cspan>36360\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@saveasmoker.com\"> info@saveasmoker.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 21, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Erick Slaick:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.saveasmoker.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.saveasmoker.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Save A Smoker– Buttery Waffle and Save A Smoker – Vanilla Cinnamon Roll.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 5,900 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0001270 on September 8, 2020. However, FDA issued a negative action for PMTA STN PM0001270 in the form of a Refuse to Accept determination on May 24, 2021, which covers 1,662 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by PMTA STN PM0001270 that resulted in a Refuse to Accept determination, are adulterated and misbranded.\u003C\u002Fp>\n\n\u003Cp>All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2201727, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Save a Smoker\u003Cbr>\nAttn: Eric Slaick\u003Cbr>\n1809 Berkshire Drive\u003Cbr>\nDothan, AL 36303\u003C\u002Fp>\n\n\u003Cp>Domains By Proxy, LLC\u003Cbr>\nsaveasmoker.com@domainsbyproxy.com\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>Google LLC\u003Cbr>\ngoogle-cloud-compliance@google.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nErick Slaick\n\nSAS Technologies, Inc d\u002Fb\u002Fa Save A Smoker\n\n4074 S US Hwy 231F Suite B\n\nOzark, AL 36360\n\nUnited States\n\ninfo@saveasmoker.com\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJanuary 21, 2022\n\nWARNING LETTER\n\nDear Erick Slaick:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.saveasmoker.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.saveasmoker.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Save A Smoker– Buttery Waffle and Save A Smoker – Vanilla Cinnamon Roll.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 5,900 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0001270 on September 8, 2020. However, FDA issued a negative action for PMTA STN PM0001270 in the form of a Refuse to Accept determination on May 24, 2021, which covers 1,662 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by PMTA STN PM0001270 that resulted in a Refuse to Accept determination, are adulterated and misbranded.\n\nAll new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2201727, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nSave a Smoker\n\nAttn: Eric Slaick\n\n1809 Berkshire Drive\n\nDothan, AL 36303\n\nDomains By Proxy, LLC\n\nsaveasmoker.com@domainsbyproxy.com\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nGoogle LLC\n\ngoogle-cloud-compliance@google.com","SAS Technologies, Inc d\u002Fb\u002Fa Save A Smoker","sas-technologies-inc-dba-save-smoker-625483-01212022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsas-technologies-inc-dba-save-smoker-625483-01212022","2026-10-26T08:09:54.121663+00:00","2022-01-25","625483","Tobacco","Erick Slaick","2026-08-20T02:14:57.419+00:00","VIA UPS and Electronic Mail","2022-01-21",{"id":95,"raw":96,"subject":102,"body_html":103,"body_text":104,"firm_name":105,"letter_id":106,"created_at":107,"fei_number":19,"letter_url":108,"updated_at":109,"action_type":22,"case_status":23,"posted_date":110,"marcs_cms_no":111,"product_type":26,"closeout_date":19,"issuing_office":100,"recipient_name":19,"body_fetched_at":112,"delivery_method":113,"recipient_title":19,"reference_number":19,"action_taken_date":114,"medical_device_id":19,"response_letter_date":19},312,[97,98,99,100,101,13,13,13],"\u003Ctime datetime=\"2026-03-03T05:00:00Z\">03\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-20T05:00:00Z\">02\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmaxlife-technologies-inc-dba-maxlife-721453-02202026\">MaxLife Technologies Inc. dba Maxlife \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","False &amp; Misleading Claims\u002FMisbranded (Telehealth)","False & Misleading Claims\u002FMisbranded (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>MaxLife Technologies Inc. dba Maxlife \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>220 Technology Dr Ste. 215\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irvine\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92618\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hq@maxlife.com\"> hq@maxlife.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 20, 2026\u003C\u002Fp>\u003Cp>Maxlife:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fmaxlife.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The compounded semaglutide and tirzepatide products displayed on your website identify “Maxlife” on the pictured label, suggesting Maxlife is the compounder of those drugs when in fact it is not.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, the representations on your website that Maxlife is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“generic compounded medication”\u003C\u002Fli>\u003Cli>“With the same active ingredient as Wegovy® and Ozempic®, this treatment has been clinically tested and FDA-approved for effective weight management.”\u003C\u002Fli>\u003Cli>“With the same active ingredient as Mounjaro® and Zepbound®, this treatment has been clinically tested and FDA-approved for effective weight management.”\u003C\u002Fli>\u003Cli>“FDA Approved”\u003C\u002Fli>\u003Cli>“Active ingredients in Ozempic® &amp; Wegovy®”\u003C\u002Fli>\u003Cli>“Active ingredients in Mounjaro® &amp; Zepbound®”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations and claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\u003C\u002Fp>\u003Cp>1) Identifying the entities that produce the compounded products offered on your website;\u003C\u002Fp>\u003Cp>2) Providing a representative sample of labeling for such products; and\u003C\u002Fp>\u003Cp>3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Matthew J. Lash\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nMaxLife Technologies Inc. dba Maxlife\n\n220 Technology Dr Ste. 215\n\nIrvine, CA 92618\n\nUnited States\n\nhq@maxlife.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFebruary 20, 2026\nMaxlife:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fmaxlife.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe compounded semaglutide and tirzepatide products displayed on your website identify “Maxlife” on the pictured label, suggesting Maxlife is the compounder of those drugs when in fact it is not.2 Accordingly, the representations on your website that Maxlife is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nAdditionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n“generic compounded medication”\n“With the same active ingredient as Wegovy® and Ozempic®, this treatment has been clinically tested and FDA-approved for effective weight management.”\n“With the same active ingredient as Mounjaro® and Zepbound®, this treatment has been clinically tested and FDA-approved for effective weight management.”\n“FDA Approved”\n“Active ingredients in Ozempic® & Wegovy®”\n“Active ingredients in Mounjaro® & Zepbound®”\nCompounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations and claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\nFor the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\nYou should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\n1) Identifying the entities that produce the compounded products offered on your website;\n2) Providing a representative sample of labeling for such products; and\n3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n____________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].","MaxLife Technologies Inc. dba Maxlife","maxlife-technologies-inc-dba-maxlife-721453-02202026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmaxlife-technologies-inc-dba-maxlife-721453-02202026","2026-10-26T08:09:21.894493+00:00","2026-03-03","721453","2026-08-19T04:55:07.096+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-02-20",5,{"510k":117,"classification":118,"enforcement":119,"event":120,"event_backfill":121,"pma":122,"warning_letter":123},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]